Argos Therapeutics Inc fka ARGSQ

[blackcat]

Argos Therapeutics' late-stage study of lead product candidate AGS-003 soldiers on, next data review in February
Jun 13 2016, 10:29 ET | About: Argos Therapeutics, Inc. (ARGS) | By: Douglas W. House, SA News Editor [Contact this editor with comments or a news tip]

Based on a review by the independent Data Monitoring Committee, Argos Therapeutics (ARGS -10.8%) will continue its Phase 3 clinical trial, ADAPT, evaluating lead product candidate AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). The next data review is planned to coincide with the Genitourinary Cancers Symposium in February 2017. A positive outcome will trigger the second tranche of financing under its March 2016 securities purchase agreement which will net the company almost $30M via the sale of 5,478,672 shares of common stock and warrants to purchase 4,109.005 shares of common.

The primary analysis and assessment of overall survival should happen in H1 2017.

Several months ago, the company cut 13% of its workforce in order to conserve resources as ADAPT progresses.

AGS-003 is an individualized immunotherapy designed to induce a memory T cell response specific to each patient's cancer. It is produced using a small sample of RNA from the patient's tumor and dendritic cells derived from cells collected from the patient.